GSK PLC

European pharma and biotech firms face volatile markets; learn how GSK and others use value‑based pricing, early approvals, and M&A to beat patent cliffs and drive growth.

GSK’s bepirovirsen hits a 20 % functional cure in phase‑III HBV trials, offering a premium, one‑time treatment that could reshape global pricing, reimbursement, and investor sentiment.

GSK’s May share‑repurchase boosts EPS modestly, yet its stock remains flat amid competitive pricing pressures, LOER risks, and a focus on value‑based reimbursement and pipeline strength to protect profitability and shareholder value.

GSK plc completes Pfizer exit from ViiV Healthcare, boosts its stake and executes a £2,000‑pence share buy‑back—optimising capital, governance, and shareholder value.

GSK’s first‑quarter approvals in China—Exdensur for severe asthma and bepirovirsen for hepatitis B—promise cost‑effective, value‑based therapies that boost clinical outcomes while easing payer budgets.

GSK’s rising oncology sales, FDA‑approved companion diagnostic and new value‑based contracts boost its precision‑medicine strategy, while a focused regulatory hub and cost‑efficiency plans keep the pharma group on a path to robust cash flow and shar…

GSK’s latest share‑buyback and strategic pipeline moves show how a pharma giant balances market access, patent cliffs, and high‑margin R&D to protect shareholder value amid volatile macro‑economic conditions.

GSK PLC expands its global therapeutic reach with approvals for bepirovirsen in Japan, priority reviews in China and Japan, and robust Cabenuva data for adolescents—showcasing safety‑focused, market‑driven progress across infectious, liver, and rare…

GSK’s new siRNA partnership and Bora manufacturing extension promise pipeline resilience, cost savings, and a strong ROI, positioning the company ahead of rivals in the growing RNA therapeutics market.

GSK PLC’s analyst upgrades reveal why investors see steady growth: robust earnings, diverse portfolio, cost cuts, and a strong pipeline that outpaces peers like Pfizer and Novartis.